Kornimate/medical-research-clean huggingface dataset:
diabetes footcare companion app for patients and carers

Conditions: Diabetes Mellitus Foot Ulcer; Diabetes Mellitus, Type 2; Diabetic Foot; Diabetic Foot Infection; Ulcer Foot; Ulcer, Leg

Summary: diabetes education and self-management support can be delivered via mobile phones. this protocol aims to assess the feasibility and acceptability of well feet, a conversational agent, as a diabetic foot care companion. by utilizing feedback and responses to evaluative questions posted on the app's interface, the investigators intend to examine the app's technical, functional, and operational feasibility.

diabetes puts patients with diabetes at risk of foot complications. besides well managed diabetes, providing diabetes foot care education and self-management support is key to reducing the risk of developing diabetic foot ulcers, a serious and costly complication of diabetes. although, education and self-management support for people with diabetes can improve patients' quality of life, they are still commonly not provided or inadequate. digital technologies have the potential to offer a new convenient, interactive, and engaging mode of self-management education and support. this study aims to examine the feasibility of the well feet app for diabetes foot care education and self-management support in promoting optimal foot care behaviour. in recognizing that many people with diabetes, especially the elderly, require the support of informal carers, the app also targets their knowledge and support needs.

Eligibility criteria:
inclusion criteria for patients: 1. patients diagnosed with type 2 diabetes and attending tan tock seng hospital diabetes clinic 2. aged 21 years or above 3. able to speak and read english 4. own a smartphone or tablet 5. can download the app 6. have internet access 7. able to give informed consent 8. singapore nationality or permanent residents inclusion criteria for carers: 1. provide care for a type 2 diabetes patient for the past 6 months 2. aged 21 years or above 3. able to speak and read english 4. own a smartphone or tablet 5. can download the app 6. have internet access 7. able to give informed consent exclusion criteria for patients and carers: 1. pregnant 2. inpatient 3. received formal training in medicine or allied health services

Keywords: conversational agent chatbot diabetes literacy diabetes knowledge self management digital therapeutics digital health
the use of breathing synchronized ct and pet scans in radiation therapy treatment planning

Conditions: Lung Cancer; Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to find out whether a new device can help obtain more accurate ct and pet scans of the lungs and chest tumors and the liver and liver tumors to help in delivering radiation therapy. when we breathe, the amount of air in the lung changes. lung tumors may also move during breathing. liver tumors may also move with breathing; as the lungs inflate, the liver can be pushed down. a ct scan (a special type of x-ray) is routinely obtained as part of planning for lung or liver radiation therapy. since patients breathe during this ct scan and their lung or liver tumors move, these ct scans can sometimes be inaccurate. we are now testing a device to only obtain the ct and an additional pet scan while patients are breathing in or out. this will hopefully allow us to deliver radiation with more accuracy.

the objectives are to measure the amount of tumor motion with respiration, measure changes in tumor definition with breathing synchronized pet compared to standard free breathing pet, and to determine the fraction of patients whose radiation treatment plans would be modified based on this information. eligible patients are those receiving radiation treatment for thoracic or liver tumors.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * ability to sign informed consent form indicating investigative nature of this study, in keeping with the policies of the hospital. * patients must have thoracic disease visible on a chest ct scan, or liver disease visible on a abdominal ct scan. exclusion criteria: * pregnant women are ineligible. a pregnancy test will be performed on each fertile premenopausal female prior to entry into the study. * patients with thoracic or liver disease that is not visible on ct scan * patients who are unable to follow directions either due to language difficulties or hearing impairment. * patients who are too ill to hold their breath.
central and peripheral fatigue in individuals with parkinson's disease - evaluation and training

Conditions: Parkinson Disease(PD)

Summary: fatigue is one of the most common symptoms in individuals with parkinson's disease (pd). past research indicated that more than half of the individuals with pd demonstrated fatigue symptom. the severity of fatigue was also correlated to the quality of life in individuals with pd. finding the contributions of the central and the peripheral factors to fatigue and developing an effective training program for individuals with pd are very important. fatigue can be categorized into peripheral or central causes. the central fatigue and voluntary activation failure originate from the decrease in motivation or the reduction of the conduction within corticospinal tracts. long term activation failure and central fatigue will cause disuse of muscle and result in peripheral weakness and peripheral fatigue. quantifying the weighting of central versus peripheral factors contributing to the fatigue in people with pd is important. most of the conventional strength and endurance training programs were based on the researches of young groups. almost no training program was design for enhancing the voluntary activation level and relief the central fatigue. seeking an appropriate training program to enhance central activation is very important for individuals with pd who prone to fatigue. previous studies have shown that increasing afferent input by peripheral electrical stimulation (es) at sensory threshold enhanced the plasticity of contralateral primary sensory cortex, the excitability of corticospinal tracts, and the functional performance in young adults. combining afferent input with strength training was more effective than strength training along. es, which is easy to quantify the dose of afferent input, is a feasible method to provide such training. the purpose of this project is to investigate the effects of the combination of es at sensory threshold and strength training on voluntary activation in the individuals with pd.


Eligibility criteria:
health subjects: exclusion criteria: * musculoskeletal injuries for knee. * osteoporosis. * diabetes. pd subjects: inclusion criteria: * clinical diagnosis of parkinson disease. exclusion criteria: * musculoskeletal injuries for knee. * osteoporosis. * diabetes. * any peripheral or central nervous system injury or disease patients.

Keywords: muscle strength, fatigue, electromyography (emg), central fatigue, strength straining
lid wipes versus baby shampoo in patients with seborrehic blepharitis

Conditions: Seborrheic Blepharitis

Summary: the purpose of this study is to investigate the efficacy of lid wipes containing terpinen-4-ol and sodium hyaluronate (hy-ter®) for the treatment of seborrheic blepharitis compared to baby shampoo.

after being informed about the study and potential risks, all patients giving written consent will have a complete ophthalmological examination to determine eligibilty for study entry. at week 0, patients who meet the eligibility requirements will be randomized in a double blind manner (participant and investigator) in a 1:1 ratio to lid wipes containing terpinen-4-ol and sodium hyaluronate (hy-ter®) or baby shampoo (twice daily).

Eligibility criteria:
inclusion criteria: * diagnosis of seborrheic blepharitis exclusion criteria: * patients with ophthalmological pathologies that may affect the tear film functions including ocular rosacea, contact lens use, history of any ocular surgery, or patients with systemic pathologies or those using systemic medications that may affect the tear film functions * patients younger than 18-year-old * patients who used any treatment for blepharitis within the 6 months prior to the examination

Keywords: seborrheic blepharitis terpinen-4-ol baby shampoo lid wipes sodium hyaluronate
evolusion study using the zyga simmetry sacroiliac joint fusion system

Conditions: Sacroiliac Joint Dysfunction

Summary: sacroiliac joint pain reduction and radiographic evidence of sij fusion will be collected to evaluate clinical performance of the simmetry sacroiliac joint fusion system.

this is a prospective, non-randomized post market study designed to evaluate fusion and pain reduction following the use of the simmetry system. this study will be conducted at up to 40 sites and 250 total subjects will be enrolled and followed through 24 months. data will be collected pre-operatively, implant, and at specified follow-up time points through 24 months.

Eligibility criteria:
key inclusion criteria: * at least three positive provocative tests for sij pain * non-operative management of sij pain for ≥ 6 months prior to surgery * at least one positive diagnostic sij injection resulting in a ≥ 50% decrease in pain * vas back pain score of ≥ 60 mm * the subject is at least 18 years of age key exclusion criteria: * trauma causing fracture of the sacrum or iliac bones or has had spinal trauma leading to a neurological deficit, or pelvic soft tissue or bony tumors * pregnant or is planning on becoming pregnant in the next two years * chemical dependency abuse problems as evidenced by a history of abusing drugs which is documented in their past medical history or is elicited from an interview. * receiving or seeking worker's compensation, disability remuneration, and/or involved in litigation related to low back or sij pain * history of significant emotional or psychosocial disturbance

Keywords: sacroiliac joint fusion sij fusion si joint sij
the effect of early mobilization training on mobility, pain and comfort after abdominal surgery

Conditions: Abdominal Surgery

Summary: the primary aim of this study is to examine the effects of in-bed rotation and early mobilization training given before abdominal surgery on mobility, pain and comfort of patients after surgery. the secondary aim of the study is to examine the effect of mobilization training given before abdominal surgery on the sleep of patients after surgery.

the primary aim of this clinical trial study is to examine the effects of early mobilization training given before abdominal surgery on mobility, pain and comfort of patients after surgery. the secondary aim of the study is to examine the effect of mobilization training given before abdominal surgery on the sleep of patients after surgery. research hypotheses are: h11. there is a difference between the mobility scores of the patients who were given and not given pre-abdominal surgery training. h12. there is a difference between the comfort scores of patients who were given and not given pre-abdominal surgery training. h13. there is a difference between the sleep scores of the patients who were given and not given pre-abdominal surgery training. first, the patient's mobility status in the preoperative period was evaluated with these scales. "early mobilization training" will be given to the patients in the intervention group in the preoperative period. "early mobilization training material" to be prepared by the researcher will be used as training material. the training content will include information about the techniques and points to be considered about turning from one side to the other in the bed, sitting on the side of the bed, standing on the side of the bed and walking in the patient's room, and the time spent outside the bed on the day of surgery and the first and subsequent days after surgery. after the patient's mobilization on the first day after the operation, the patient mobility scale, the postoperative mobilization, the visual analogue scale (vas) questions questioning the pain and comfort during lying and sitting, and sleep status will be filled.

Eligibility criteria:
inclusion criteria: * over 18 years old * those with abdominal surgery exclusion criteria: -

Keywords: abdominal surgery early mobilization
open label immunotherapy trial for breast cancer

Conditions: Breast Cancer

Summary: this phase ii will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. investigators will test new tableted preparation, v3-mommo, obtained from hydrolyzed, inactivated blood and tumors of patients with breast cancer. study will last 3 months, 20 patients will be recruited, given one pill per day for three months. the primary clinical endpoint is effect on tumor size and burden after 3 months. secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

worldwide, breast cancer is the number one cancer in women. it affects about 12% or 1.7 mln women worldwide. in mongolia breast cancer is less common, occupies 5-th place by frequency in women, the incidence is 118 per 100,000 or 1,770 cases per year. many different types of immunotherapy (especially checkpoint inhibitors) are being tested, but so far the successes have been insignificant, and serious side effects are frequent and unpredictable. this phase ii will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. investigators will test new tableted preparation, v3-mommo, obtained from hydrolyzed, inactivated blood and tumor tissues of patients with breast cancer. study will last 3 months, 20 patients will be recruited, given one pill per day for three months. the primary clinical endpoint is effect on tumor size and lymph nodes burden after 3 months. secondary endpoint will be effect on levels of tumor markers (i.e., cancer antigen 15-3 (ca 15-3), cancer antigen 27.29 (ca 27.29), and carcinoembryonic antigen (cea) on monthly basis compared to baseline.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of breast cancer positive at least for cea tumor marker at above normal threshold level exclusion criteria: * mastectomy
safety of phenylephrine hydrochloride, acetaminophen, dimethindene maleate compared to phenylephrine hydrochloride alone in healthy volunteers

Conditions: Heart Rate; Blood Pressure; Arrhythmias

Summary: this study will evaluate the safety of phenylephrine hydrochloride 10 mg + acetaminophen 500 mg + dimethindene maleate 1 mg compared to phenylephrine hydrocloride 10 mg alone in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy volunteers between 18 and 50 years; * clinical examination without abnormal findings * ability to understand the nature and purpose of the study, including the risks and adverse effects exclusion criteria: * any cardiovascular disease, coronary artery disease, circulation problems or history of stroke, peripheral vascular disease or arrhythmia * history of serious adverse reactions or hypersensitivity any drug * hypersensitivity to the drug study drugs or chemically related compounds

Keywords: safety heart rate systolic and diastolic blood pressure arrhythmias
re-treatment study of probuphine in opioid addiction

Conditions: Opioid Dependency

Summary: probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (bpn). bpn is an approved treatment for opioid dependence. this is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of probuphine in patients who have previously completed the 6-month pro-806 study with either probuphine, placebo or sublingual buprenorphine.


Eligibility criteria:
inclusion criteria: * subject has voluntarily provided written informed consent prior to conducting any study-related procedures * completion of 24 weeks of treatment in pro-806 * subject has been deemed appropriate for entry into this extension study by the investigator * females of childbearing potential must be willing to use a reliable means of contraception during the entire study. exclusion criteria: * an aspartate aminotransferase (ast) levels ≥ 3 x the upper limit of normal, alanine aminotransferase (alt) levels ≥ 3 x the upper limit of normal, total bilirubin ≥ 1.5 x the upper limit of normal, or creatinine ≥ 1.5 x upper limit of normal on the screening laboratory assessments * a current diagnosis of chronic pain requiring opioids for treatment * a pregnant or lactating female * current use of agents metabolized through cytochrome p450 3a4 (cyp 3a4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) * a history of coagulopathy within the past 90 days, and/or current anti-coagulant therapy such as warfarin * a significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the investigator would preclude compliance with the protocol, subject safety, adequate cooperation in the study, or obtaining informed consent * any current medical conditions such as severe respiratory insufficiency that may prevent the subject from safely participating in study, or any pending legal action that could prohibit participation or compliance in the study

Keywords: opioid dependence opioid addiction buprenorphine implant methadone heroin suboxone opioid pain medication opioid withdrawal
study of oral venetoclax tablets in combination with intravenous obinutuzumab injection to assess achievement of best response in adult participants with chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia (CLL)

Summary: chronic lymphoid leukemia (cll) is the most common type of leukemia (cancer of blood cells) in adults affecting men more so than women. the main objective of this study is to assess the how effective venetoclax (venclexta) in combination with obinutuzumab is in treating chronic lymphocytic leukemia (cll). effectiveness is assessed by achievement of best response. venetoclax is an approved drug developed for the treatment of cll. approximately 50 adult participants with previously untreated cll will be enrolled in approximately 10 to 15 sites in russian federation. participants will receive oral venetoclax tablets in combination with intravenous (iv) obinutuzumab as prescribed by the physician prior to enrolling in this study in accordance to the local practice and label. there may be a higher burden for participants in this study compared to standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of previously untreated chronic lymphocytic leukemia (cll). * participant for whom the physician has decided to initiate cll treatment with venetoclax combo therapy with obinutuzumab, according to approved local label up to 4 weeks (28 days) after obinutuzumab treatment initiation. exclusion criteria: * contraindications to venclexta (venetoclax) as listed on the approved local label in russian federation. * creatinine clearance \< 30 millilitres/minute. * richter syndrome or transformation of cll to aggressive non-hodgkin lymphoma. * participating in a clinical trial with an investigative drug for cll.

Keywords: chronic lymphocytic leukemia (cll) venetoclax venclexta obinutuzumab cancer
mesenchymal stem cell therapy (mscs) and conditioned medium therapy for osteoartrithis

Conditions: Osteoarthritis, Knee

Summary: this study aims to compare the efficacy of umbilical cord mesenchymal stem cell and secretome between arthroscopy and without arthroscopy intervention in oa patients. this study has 4 arms namely arthroscopy + booster, arthroscopy + pre-conditioning, non-arthroscopy + booster, non-arthroscopy + pre-conditioning.

the study subjects each group amounted to 5 patients suffering from osteoarthritis. patients are evaluated before, and 1,3,6 months after injection.

Eligibility criteria:
inclusion criteria: * patients aged 55-70 years * suffering from grade 2-3 oa was identified by two observers who differed accordingly kellgren-lawrence research scale * absence of local or general infections * haematological and biochemical analysis without significant changes being made cause contraindications * patients can understand the nature of the study * written informed consent is given to patients exclusion criteria: * patients are not willing to obey the study protocol * there are signs of infection or positive serology for hiv, hepatitis and syphilis * there is a history of cancer both in the family and yourself and the value of the examination tumour marker exceeds normal limits * there is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results * articular injection of the knee by any drug during the previous 3 months * participate in any clinical trial or treatment 30 days before the study * other conditions may, according to medical criteria, not support participation in this research * patients are subordinates or low ranking members

Keywords: osteoarthritis allogeneic mesenchymal stem cells umbilical cord conditioned medium
routine preoperative hemostatic laboratory evaluation prior to tonsillectomy or adenoidectomy in children

Conditions: Coagulation Abnormalities

Summary: routine analysis of coagulation profile is recommended before adenoidectomy, tonsillectomy or ventilation tubes insertion in children. a proportion of those children reveal borderline abnormal values of partial prothrombin time (aptt) or prothrombin time (pt) and then they are referred to a consultant hematologist for further evaluation and recommendations before surgery. the purpose of this study is to summarize the causes of referrals in a cohort of 200 children and to assess the further laboratory analysis preformed and the results obtained.

data from about 200 children that were evaluated for abnormal coagulation tests performed before minor surgery. the data will include cause of referral, laboratory analysis performed and results. if the data allows the outcome of the operation and bleeding complications, will also recorded.

Eligibility criteria:
inclusion criteria: * all the patients referred to the pediatric hematology unit for evaluation due to coagulation abnormalities before minor surgery exclusion criteria: * no exclusion are applicable

Keywords: adenoidectomy tonsillectomy ventilation tubes preoperational screening coagulation profile lupus anticoagulant
long-term efficacy and safety of growth hormone replacement therapy in chronic heart failure

Conditions: Growth Hormone Deficiency; Chronic Heart Failure

Summary: after the encouraging results of 6 months of growth hormone replacement therapy in patients with chronic heart failure and coexisting growth hormone deficiency (nct00591760) the investigators wanted to collect data about the long-term efficacy and safety of this kind of therapy.


Eligibility criteria:
inclusion criteria: * chronic heart failure new york heart association functional class ii to iv, secondary to ischemic or idiopathic cardiomyopathy * age range 18-80 years * stable medication for at least one month including beta-blockers that had to be started at least 5 months before entering the study * left ventricular ejection fraction 40% or less * growth hormone deficiency (defined as a peak gh response to intravenous stimulation with ghrh + arginine \< 9 ng/ml) * written informed consent exclusion criteria: * acute proliferative or severe non-proliferative diabetic retinopathy * active malignancy * evidence of progression or recurrence of an underlying intracranial tumor * unstable angina or recent myocardial infarction * serum creatinine levels \> 2.5 mg/dl * severe liver disease (child-pugh b-c)